文献速递皮肤肿瘤

肢端皮肤CD8+淋巴增殖性疾病中KIR3DL1的致癌性改变

Oncogenic alterations in KIR3DL1 in cutaneous acral CD8+ lymphoproliferative disorder.
PubMed 文献 · Br J Dermatol · 2024-01-01

该德国研究对5例肢端皮肤CD8+ T细胞淋巴增殖性疾病(TLPD)进行全外显子及靶向测序,发现2例存在KIR3DL1纯合缺失,且所有病例均丢失KIR3DL1蛋白表达;另1例携带PIK3R1功能丧失突变。KIR3DL1改变可能参与发病,其蛋白丢失有助于诊断但非亚型特异性。

要点

  • 肢端CD8+ TLPD中KIR3DL1基因缺失导致蛋白表达丢失,所有分析病例均阴性。
  • KIR3DL1表达丢失在其他CD8+皮肤T细胞淋巴瘤中仅50%(6/12)阳性,非亚型特异。
  • KIR3DL1免疫组化可作为辅助诊断指标,但需结合其他特征鉴别侵袭性淋巴瘤。

核心结论

  • KIR3DL1基因改变可能对肢端CD8+ TLPD具有致病相关性。
  • KIR3DL1蛋白表达丢失可支持该惰性淋巴瘤的诊断,但并非亚型特异性鉴别特征。

研究设计与样本

  • 德国研究,对5例肢端皮肤CD8+ TLPD的石蜡包埋组织进行全外显子组和靶向测序。
  • 采用免疫组化检测相关蛋白表达,并以12例CD8+皮肤T细胞淋巴瘤作为KIR3DL1染色对照。

主要发现

  • 拷贝数变异分析显示2/5例存在KIR3DL1基因纯合缺失。
  • 所有肢端CD8+ TLPD病例均观察到KIR3DL1蛋白表达丢失。
  • 其他CD8+皮肤T细胞淋巴瘤中KIR3DL1表达更可变,50%(6/12)病例为阳性。
  • 另1例肢端CD8+ TLPD携带PIK3R1基因功能丧失突变,推测激活PI3K-AKT通路。

关键数值与推荐

  • KIR3DL1蛋白表达丢失见于所有分析的肢端CD8+ TLPD病例。
  • 其他CD8+皮肤T细胞淋巴瘤中KIR3DL1阳性率为50%(n=12)。

临床怎么用

  • KIR3DL1免疫组化染色可作为肢端CD8+ TLPD的辅助诊断工具。
  • 诊断时需注意KIR3DL1丢失并非该亚型独有,应结合临床及CD68等标志物综合判断。

局限性

  • 研究仅纳入5例肢端CD8+ TLPD,样本量小。
  • KIR3DL1表达丢失并非亚型特异性,鉴别诊断价值有限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Primary cutaneous acral CD8+ T-cell lymphoproliferative disorder (TLPD) is a rare and indolent lymphoma entity. Although TLPD was first identified many years ago, the molecular pathogenesis is still not fully understood. OBJECTIVES: In order to better understand the molecular pathogenesis of cutaneous acral CD8+ TLPD and to identify further discriminatory markers to differentiate this lymphoma subtype from other CD8+ cutaneous lymphomas, we analysed five cases of cutaneous acral CD8+ TLPD for putative molecular alterations. METHODS: Somatic alterations were assessed using whole-exome and targeted sequencing of paraffin-embedded tissue. Results were evaluated using immunohistochemical staining of respective relevant proteins. CD8+ cutaneous T-cell lymphomas (n = 12) served as control for KIR3DL1 staining. RESULTS: Copy number variation analysis revealed a homozygous deletion of the KIR3DL1 gene in two of the analysed cases. This resulted in loss of KIR3DL1 protein expression, which was observed in all cases of cutaneous acral CD8+ TLPD. In contrast, KIR3DL1 expression was more variable in other CD8+ cutaneous T-cell lymphomas with 50% of analysed cases (n = 12) found to be positive. In addition, one further case of acral CD8+ TLPD harboured a loss-of-function mutation in the PIK3R1 gene, presumably activating the phosphoinositide 3-kinase-AKT pathway. CONCLUSIONS: Alterations of the KIR3DL1 gene may be of pathogenetic relevance for acral CD8+ TLPD. Loss of KIR3DL1 protein expression may support the diagnosis of this indolent lymphoma entity; however, this is not a subtype-specific discriminative feature. Cutaneous acral CD8+ T-cell lymphoproliferative disorder (TLPD) is a very rare form of lymphoma, with only around 60 cases reported worldwide. The progression of this lymphoma is usually slow, and most people will present with a solitary plaque or a small papule, without any risk of rapid worsening. For this reason, treatment directly on the skin with topical steroids, excision or radiation are usually sufficient. However, it can be difficult to differentiate this type of lymphoma from other CD8+ cutaneous types upon microscopy. This is important because other CD8+ cutaneous lymphomas can follow an aggressive course and will need to be treated differently, using systemic therapies. Previous findings have shown that abnormal expression of a protein (called CD68) in a dotlike pattern is a specific feature of acral CD8+ TLPD and could help to accurately diagnose this lymphoma. Until now, the underlying molecular differences in cutaneous acral CD8+ TLPD have not been identified. Therefore, this German study was carried out to look at the genetic alterations in the tissue of five patients with this type of lymphoma. To do this, we used a method that examined whole-exome and targeted gene sequencing. We detected alterations in a gene important for T-cell function (called KIR3DL1), in two of five analysed cases. Of note, a loss of KIR3DL1 protein expression has been observed in all analysed cases of acral CD8+ TLPD. Our study findings suggest that genetic defects in KIR3DL1 in acral CD8+ TLPD could be a novel diagnostic marker for this lymphoma subtype and may help to better distinguish it from other, potentially aggressive forms of cutaneous lymphoma.

来源:Br J Dermatol,查看原文。版权归原作者所有。

引用

  1. Wobser M, Appenzeller S, Roth S, et al. Oncogenic alterations in KIR3DL1 in cutaneous acral CD8+ lymphoproliferative disorder. Br J Dermatol. 2024. PMID: 38924750. doi:10.1093/bjd/ljae256

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。